Groundbreaking global survey captures the significant patient burden experienced with current standard-of-care bladder cancer treatments, underscoring urgency for continued innovation
Go back to Groundbreaking global survey captures the significant patient burden experienced with current standard-of-care bladder cancer treatments, underscoring urgency for continued innovation| Johnson & Johnson (NYSE: JNJ) | Delayed: 235.26 +3.97 (1.72%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $231.29 | 52 Week High | $126.07 | |||
| Open | $235.64 | 52 Week Low | $94.28 | |||
| Day High | $237.85 | P/E | 48.91 | |||
| Day Low | $234.35 | EPS | $4.81 | |||
| Volume | 2,461,831 | |||||
| (NASDAQ: STGW) | Delayed: 6.88 +0.22 (3.30%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $6.66 | 52 Week High | $ | |||
| Open | $6.62 | 52 Week Low | $ | |||
| Day High | $6.94 | P/E | N/A | |||
| Day Low | $6.62 | EPS | $ | |||
| Volume | 531,757 | |||||
